Cellceutix antibiotic brilacidin gains 'infectious disease' status
This article was originally published in Scrip
Executive Summary
The FDA has granted qualified infectious disease product (QIDP) status to Cellceutix's antibiotic brilacidin, which the firm is developing as a treatment for acute bacterial skin and skin structure infections (ABSSSI).